Inhaled treprostinil for COPD with low oxygen
Treatments studied
Part of Lungs & breathing clinical trials.
This trial tests an inhaled medication called treprostinil (Tyvaso) to see if it can help people with COPD who have low blood oxygen levels. You may qualify if you have chronic bronchitis, use oxygen at rest or during exercise, and meet specific lung function criteria.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 40 years of age or older.
- You have chronic bronchitis (a cough with mucus most days for at least 3 months in two years).
- You are a current or former smoker with at least 20 pack-years of smoking history.
- You have COPD confirmed by lung function tests, with moderate to severe airflow limitation.
- You use supplemental oxygen at rest or during exercise (up to 4 liters per minute).
- You are on stable COPD medications (no changes in the last 3 months).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new inhaled drug, HSK39004, to see if it safely improves breathing and quality of life in people with moderate to severe COPD. You may join if you are between 40 and 80, have a COPD diagnosis with certain lung function results, and have at least some shortness of breath with daily activities.
This trial tests whether an inhaled medication called treprostinil can improve exercise ability in people with exercise-induced pulmonary hypertension. It aims to see if the drug helps with shortness of breath during activity.
This trial tests an inhaled medicine (TPIP) for people with both lung scarring (interstitial lung disease) and high blood pressure in the lungs (pulmonary hypertension). It aims to see if the drug helps improve exercise ability and symptoms.
This trial tests if treprostinil can help people with pulmonary arterial hypertension (PAH) who are at intermediate risk. You may join if you have been diagnosed with certain types of PAH and meet specific heart and lung test results.
This Phase 3 trial tests whether inhaled treprostinil can slow progression of lung fibrosis (scarring) that keeps getting worse despite standard care. It also looks at safety, because inhaled medicine can cause side effects and needs careful monitoring.
This study looks at how well the drug Treprostinil works in people with a specific type of pulmonary hypertension (high blood pressure in the lungs). It helps researchers understand real-world results and side effects.
Hear when a new Hypoxemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.